{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:00:26.222646",
  "document": "02_Article_AAV Management Guidelines.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/02_Article_AAV Management Guidelines.pdf",
  "pipeline_version": "0.8",
  "total_recommendation_sets": 1,
  "total_recommendations": 17,
  "recommendation_sets": [
    {
      "guideline_name": "EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update",
      "guideline_year": 2022,
      "organization": "EULAR",
      "target_condition": "ANCA-associated vasculitis",
      "target_population": null,
      "recommendations": [
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_1",
          "recommendation_type": "treatment",
          "population": "patients with suspected AAV",
          "condition": "new diagnosis or suspected relapsing",
          "severity": "na",
          "action": "biopsy to assist in establishing diagnosis",
          "action_description": null,
          "preferred": "tissue biopsy",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "low",
          "strength": "weak",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "A positive biopsy is strongly supportive of a diagnosis of vasculitis and we recommend biopsies to assist in establishing a new diagnosis of AAV and for further evaluation of patients suspected of having relapsing vasculitis.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_2",
          "recommendation_type": "treatment",
          "population": "patients with signs/symptoms suspicious for AAV",
          "condition": "suspected AAV",
          "severity": "na",
          "action": "test for both PR3-ANCA and MPO-ANCA using high-quality antigen-specific assay",
          "action_description": null,
          "preferred": "antigen-specific assay as primary method",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "strong",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "In patients with signs and/or symptoms raising suspicion of a diagnosis of AAV, we recommend testing for both PR3-ANCA and MPO-ANCA using a high-quality antigen-specific assay as the primary method of testing.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_3",
          "recommendation_type": "treatment",
          "population": "patients with new-onset or relapsing GPA or MPA",
          "condition": "new-onset or relapsing",
          "severity": "organ-threatening or life-threatening",
          "action": "combination of glucocorticoids and either rituximab or cyclophosphamide",
          "action_description": null,
          "preferred": "rituximab in relapsing disease",
          "alternatives": [
            "cyclophosphamide"
          ],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "strong",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For induction of remission in patients with new-onset or relapsing GPA or MPA with organ-threatening or life-threatening disease, we recommend treatment with a combination of glucocorticoids and either rituximab or cyclophosphamide. Rituximab is preferred in relapsing disease.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_4",
          "recommendation_type": "treatment",
          "population": "patients with GPA or MPA",
          "condition": "induction of remission",
          "severity": "non-organ-threatening or non-life-threatening",
          "action": "combination of glucocorticoids and rituximab",
          "action_description": null,
          "preferred": "rituximab",
          "alternatives": [
            "methotrexate",
            "mycophenolate mofetil"
          ],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For induction of remission of non-organ-threatening or non-life-threatening GPA or MPA, treatment with a combination of glucocorticoids and rituximab is recommended. Methotrexate or mycophenolate mofetil can be considered as alternatives to rituximab.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_5",
          "recommendation_type": "treatment",
          "population": "patients with GPA or MPA receiving induction therapy",
          "condition": "induction of remission",
          "severity": "na",
          "action": "oral glucocorticoids starting dose 50-75 mg prednisolone equivalent/day",
          "action_description": null,
          "preferred": "50-75 mg prednisolone equivalent/day depending on body weight",
          "alternatives": [],
          "dosing": [],
          "taper_target": "5 mg prednisolone equivalent per day by 4-5 months",
          "duration": "4-5 months to target dose",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "strong",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "As part of regimens for induction of remission in GPA or MPA, we recommend treatment with oral glucocorticoids at a starting dose of 50-75 mg prednisolone equivalent/day, depending on body weight. We recommend stepwise reduction in glucocorticoids according to table 4 and achieving a dose of 5 mg prednisolone equivalent per day by 4-5 months.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_6",
          "recommendation_type": "treatment",
          "population": "patients with GPA or MPA",
          "condition": "induction of remission",
          "severity": "na",
          "action": "avacopan in combination with rituximab or cyclophosphamide may be considered",
          "action_description": null,
          "preferred": "na",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "Avacopan in combination with rituximab or cyclophosphamide may be considered for induction of remission in GPA or MPA, as part of a strategy to substantially reduce exposure to glucocorticoids.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_7",
          "recommendation_type": "treatment",
          "population": "patients with GPA or MPA",
          "condition": "induction of remission",
          "severity": "serum creatinine >300 µmol/L due to active glomerulonephritis",
          "action": "plasma exchange may be considered; routine use for alveolar haemorrhage not recommended",
          "action_description": null,
          "preferred": "na",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "Plasma exchange may be considered as part of therapy to induce remission in GPA or MPA for those with a serum creatinine >300 pmol/L due to active glomerulonephritis. Routine use of plasma exchange to treat alveolar haemorrhage in GPA and MPA is not recommended.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_8",
          "recommendation_type": "treatment",
          "population": "patients with GPA or MPA with refractory disease",
          "condition": "refractory to induction therapy",
          "severity": "na",
          "action": "thorough reassessment of disease status and comorbidities",
          "action_description": null,
          "preferred": "management by vasculitis expertise center",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "expert_opinion",
          "strength": "weak",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For patients with GPA or MPA with disease refractory to therapy to induce remission, we recommend a thorough reassessment of disease status and comorbidities and consideration of options for additional or different treatment. These patients should be managed in close conjunction with, or referred to, a centre with expertise in vasculitis.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_9",
          "recommendation_type": "treatment",
          "population": "patients with GPA and MPA",
          "condition": "maintenance of remission",
          "severity": "na",
          "action": "treatment with rituximab",
          "action_description": null,
          "preferred": "rituximab",
          "alternatives": [
            "azathioprine",
            "methotrexate"
          ],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "strong",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For maintenance of remission of GPA and MPA, after induction of remission with either rituximab or cyclophosphamide, we recommend treatment with rituximab. Azathioprine or methotrexate may be considered as alternatives.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_10",
          "recommendation_type": "treatment",
          "population": "patients with GPA and MPA",
          "condition": "maintenance therapy",
          "severity": "na",
          "action": "continue maintenance therapy for 24-48 months",
          "action_description": null,
          "preferred": "24-48 months duration",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "24-48 months following induction of remission",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "We recommend that therapy to maintain remission for GPA and MPA be continued for 24—48 months following induction of remission of new-onset disease. Longer duration of therapy should be considered in relapsing patients or those with an increased risk of relapse, but should be balanced against patient preferences and risks of continuing immunosuppression.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_11",
          "recommendation_type": "treatment",
          "population": "patients with new-onset or relapsing EGPA",
          "condition": "new-onset or relapsing",
          "severity": "organ-threatening or life-threatening",
          "action": "combination of high-dose glucocorticoids and cyclophosphamide",
          "action_description": null,
          "preferred": "cyclophosphamide",
          "alternatives": [
            "rituximab"
          ],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "moderate",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For induction of remission in new-onset or relapsing EGPA with organ-threatening or life-threatening manifestations, we recommend treatment with a combination of high-dose glucocorticoids and cyclophosphamide. A combination of high-dose glucocorticoids and rituximab may be considered as an alternative.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_12",
          "recommendation_type": "treatment",
          "population": "patients with new-onset or relapsing EGPA",
          "condition": "new-onset or relapsing",
          "severity": "without organ-threatening or life-threatening manifestations",
          "action": "treatment with glucocorticoids",
          "action_description": null,
          "preferred": "glucocorticoids",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "moderate",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For induction of remission in new-onset or relapsing EGPA without organ-threatening or life-threatening manifestations, we recommend treatment with glucocorticoids.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_13",
          "recommendation_type": "treatment",
          "population": "patients with relapsing or refractory EGPA",
          "condition": "relapsing or refractory",
          "severity": "without active organ-threatening or life-threatening disease",
          "action": "use of mepolizumab",
          "action_description": null,
          "preferred": "mepolizumab",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For induction of remission in patients with relapsing or refractory EGPA without active organ-threatening or life-threatening disease, we recommend the use of mepolizumab.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_14",
          "recommendation_type": "treatment",
          "population": "patients with EGPA",
          "condition": "maintenance of remission after organ-threatening or life-threatening disease",
          "severity": "organ-threatening or life-threatening",
          "action": "treatment with methotrexate, azathioprine, mepolizumab or rituximab should be considered",
          "action_description": null,
          "preferred": "na",
          "alternatives": [
            "methotrexate",
            "azathioprine",
            "mepolizumab",
            "rituximab"
          ],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "moderate",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For maintenance of remission of EGPA after induction of remission for organ-threatening or life-threatening disease, treatment with either methotrexate, azathioprine, mepolizumab or rituximab should be considered.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_15",
          "recommendation_type": "treatment",
          "population": "patients with relapsing EGPA",
          "condition": "maintenance of remission after non-organ-threatening manifestations",
          "severity": "non-organ-threatening or life-threatening manifestations at relapse",
          "action": "treatment with mepolizumab",
          "action_description": null,
          "preferred": "mepolizumab",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For maintenance of remission of relapsing EGPA after induction of remission for non-organ-threatening or life-threatening manifestations at the time of relapse, we recommend treatment with mepolizumab.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_16",
          "recommendation_type": "treatment",
          "population": "patients with AAV receiving rituximab",
          "condition": "receiving rituximab therapy",
          "severity": "na",
          "action": "measurement of serum immunoglobulin concentrations prior to each course",
          "action_description": null,
          "preferred": "prior to each rituximab course",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "high",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "In patients with AAV receiving rituximab, we recommend measurement of serum immunoglobulin concentrations prior to each course of rituximab to detect secondary immunodeficiency.",
          "page_num": null
        },
        {
          "recommendation_id": "rec_02_Article_AAV Management Guidelines_17",
          "recommendation_type": "treatment",
          "population": "patients with AAV receiving immunosuppressive therapy",
          "condition": "receiving rituximab, cyclophosphamide and/or high-dose glucocorticoids",
          "severity": "na",
          "action": "use of trimethoprim-sulfamethoxazole prophylaxis against Pneumocystis jirovecii pneumonia",
          "action_description": null,
          "preferred": "trimethoprim-sulfamethoxazole",
          "alternatives": [],
          "dosing": [],
          "taper_target": "na",
          "duration": "na",
          "stop_window": null,
          "evidence_level": "low",
          "strength": "conditional",
          "references": [],
          "source": "02_Article_AAV Management Guidelines",
          "source_text": "For patients with AAV receiving rituximab, cyclophosphamide and/or high doses of glucocorticoids, we recommend the use of trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis jirovecii pneumonia and other infections.",
          "page_num": null
        }
      ],
      "source_document": "02_Article_AAV Management Guidelines",
      "extraction_confidence": 0.85
    }
  ]
}